网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
华蟾素胶囊联合羟基喜树碱对中晚期食管癌疼痛患者的疗效分析
作者:杨小飞  张鹏飞 
单位:西电集团医院 消化内分泌科, 陕西 西安 710077
关键词:华蟾素胶囊 羟基喜树碱 食管癌 疗效分析 
分类号:R735.1;R273
出版年·卷·期(页码):2019·38·第十一期(1333-1336)
摘要:

目的:研究华蟾素胶囊联合羟基喜树碱用于中晚期食管癌的疗效。方法:选取2015年1月至2017年5月收治的120例食管癌患者作为研究对象,将患者依照治疗方案分为对照组和治疗组,每组60例。对照组给予羟基喜树碱,治疗组在此基础上每日给予华蟾素胶囊,比较两组患者客观缓解率、临床获益率、疼痛程度、生活质量和毒副作用,并对比两组患者治疗前后肿瘤标志物水平和1年存活率差异。结果:治疗后治疗组临床获益率、客观缓解率、生活质量显著高于对照组,疼痛程度显著轻于对照组,差异均有统计学意义(P<0.05);两组患者CEA、CA19-9和CA72-4水平改善显著优于治疗前,治疗组显著优于对照组,差异均有统计学意义(P<0.05);两组1年存活率、毒副作用方面比较,差异无统计学意义(P>0.05)。结论:华蟾素胶囊联合羟基喜树碱用于治疗中晚期食管癌疼痛,具有较好的临床效果,能够有效提高患者生活质量和临床获益率,改善肿瘤标志物水平,减轻癌痛程度,安全性较高,值得临床推广。

Objective: To study the efficacy of Cinobufagin capsule combined with hydroxycamptothecin in the treatment of patients with advanced esophageal cancer. Methods: 120 patients with esophageal cancer in our hospital from January 2015 to May 2017 were selected as the study subjects. All patients were divided into control group and treatment group according to the treatment plan, 60 cases in each. The patients in the control group were given hydroxycamptothecin, on top of which, the treatment group was given Cinobufagin capsule daily. The objective remission rate, clinical benefit rate, pain degree, quality of life and side effects were compared between the two groups. The level of tumor markers and 1-year survival rate of the two groups were compared before and after treatment. Results: After treatment, the clinical benefit rate, objective remission rate and quality of life of the treatment group were significantly higher than those of the control group. The pain degree of the treatment group was significantly lighter than that of the control group, and the difference was statistically significant (P<0.05); after treatment, the two groups of patients with CEA, CA19-9 and CA72-4 were significantly better than those before the treatment. The level of tumor markers in the treatment group was significantly better than that in the control group (P<0.05), and there was no significant difference in the 1 year survival rate and the side effects in the two groups (P>0.05). Conclusion: Cinobufagin capsule combined with hydroxycamptothecin has good clinical efficacy in the treatment of patients with advanced esophageal cancer. It can effectively improve the quality of life and the rate of clinical benefit, improve the level of tumor markers, reduce the degree of cancer pain and have high safety, which is worthy of clinical promotion.

参考文献:

[1] 中华人民共和国.中国统计年鉴2015[M].北京:中国统计出版社,2015.
[2] XIA J,INAGAKI Y,GAO J,et al.Combination of cinobufacini and doxorubicin increases apoptosis of hepatocellular carcinoma cells through the Fas- and mitochondria-mediated pathways[J].Am J Chin Med,2017,45(7):1537-1556.
[3] 肖晓光,梅齐,李扬,等.华蟾素胶囊联合化疗治疗晚期肺癌的临床研究[J].实用肿瘤杂志,2015,30(5):469-473.
[4] 柯红,崔洁,金锦莲,等.华蟾素胶囊联合CAF方案治疗中晚期乳腺癌的临床效果分析[J].世界中医药,2017,12(10):2358-2361.
[5] 李方,李楠.华蟾素胶囊联合奥沙利铂、替吉奥方案治疗中晚期结直肠癌临床疗效[J].临床军医杂志,2016,44(10):1033-1036.
[6] EDGE S B,COMPTON C C.The American Joint Committee on Cancer:the 7th edition of the AJCC cancer staging manual and the future of TNM[J].Ann Surg Oncol,2010,17(6):1471-1474.
[7] FRIENDLER A H,ETTINGER R L.Karnofsky performance status scale[J].Spec Care Dentist,2010,29(4):147-148.
[8] 严广斌.视觉模拟评分法[J/OL].中华关节外科杂志(电子版),2014,8(2):34.
[9] 美国东部肿瘤协作组.抗癌药急性及亚急性毒性反应分度标准(WHO标准)[J].癌症,1992,7(3):254-280.
[10] WATANABE H,OKADA M,KAJI Y,et al.New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)[J].Gan To Kagaku Ryoho,2009,36(13):2495-2501.
[11] 袁梅美,惠起源.华蟾素抗恶性肿瘤的研究进展[J].中国医药导报,2014,11(2):44-46.
[12] 戚诚,赵晓东,刘博,等.华蟾素胶囊联合同步放化疗治疗局部晚期食管癌的疗效分析[J].中国肿瘤临床与康复,2017,24(5):525-528.
[13] 张霞,陈迎平,祁峰.华蟾素注射液对人肝癌肿瘤细胞HepG_2增殖抑制作用观察及其作用机制研究[J].湖北中医药大学学报,2016,18(6):25-28.
[14] 薛瑞,张青松,张玉洁,等.华蟾素对乳腺癌MCF-7移植瘤裸鼠的抗肿瘤作用及机制研究[J].实用药物与临床,2014,17(7):815-817.
[15] 王宁军,芦殿荣,杨柳,等.华蟾素缓解癌性疼痛作用机制的研究进展[J].世界中西医结合杂志,2016,11(4):590-592.
[16] 贾小晴,孙萍.华蟾素抗肿瘤成分及作用机制研究进展[J].辽宁中医药大学学报,2017,19(3):215-217.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 299308 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541